Plasma stability

Aim: Screening of in vitro metabolic stability of test item in plasma from human and preclinical species.


Background information: In addition to hepatic metabolism, drugs can be metabolized by enzymes present in plasma, such as esterases. Structures containing amide and ester groups are susceptible to hydrolysis in plasma.

Drugs with rapid hydrolysis in plasma tend to have high clearance, which leads generally to poor in vivo efficacy. In case of prodrugs, plasma stability may be critical to account for their activity. In addition, plasma stability may show interspecies differences.

Plasma stability is assessed after incubation at preset time points. After stopping the reaction and centrifugation, compound is determined in the supernantant by UPLC-MS/MS.

Compound requirement: 50 µl of 10 mM DMSO solution

Turnaround time: 2 weeks / 5 compounds / 3 species

Experimental design:

Test compound concentration: 5 µM (variable on request)
Number of replicates: 2
DMSO concentration: 2%
Incubation time: 0 and 60 min (variable on request)
Control: positive control with known stability
Analytical method: UPLC-MS/MS


Delivered results:

% test compound remaining at each time point relative to time 0

Dear colleagues, collaborators, and friends,

After more than 30 years of shared endeavours, in which we have grown personally and professionally, and with our emotions on the surface, we announce the closure of our company. We have travelled together through ups and downs, celebrated successes and overcome challenges as a team.

We extend our deepest gratitude to each of you for your dedication, passion, and commitment to a shared goal: discovering new treatments for the benefit and well-being of patients.

As we bid farewell, let’s cherish the memories we’ve created, the bonds we’ve formed, and the impact we’ve made together. Though our paths may diverge, the spirit of collaboration and camaraderie that defines our community will always endure.

We leave proud of the work accomplished and thank you for being an integral part of our journey, wishing you success in all your future challenges.

With heartfelt appreciation,

Welab’s team

We are proud to announce that Welab is partner of this new EU funded project.

In collaboration with 12 partners from 6 countries, Welab Barcelona is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics. This EU funded collaboration will establish a comprehensive program for the development of broad-spectrum antiviral drugs within a five year time frame ensuring drug affordability and accessibility to low income countries.
Link to the press release: https://lnkd.in/d-jmV2CS